Close



Jan 4, 2024 07:00AM
Nov 20, 2023 04:01PM
Aug 7, 2023 04:01PM
Jun 20, 2023 07:00AM
Jun 20, 2023 07:00AM
Apr 6, 2023 07:01AM
Apr 6, 2023 07:00AM Enanta Pharmaceuticals Receives FDA Fast Track Designation for EDP-323, its Oral, L-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus
Jan 6, 2023 07:00AM
Nov 21, 2022 04:02PM
Nov 9, 2022 07:00AM
Oct 3, 2022 07:00AM
Aug 8, 2022 04:03PM
Aug 8, 2022 04:00PM
Aug 8, 2022 04:00PM Enanta Pharmaceuticals Appoints Scott T. Rottinghaus, M.D., as Senior Vice President and Chief Medical Officer
Jul 29, 2022 07:00AM
Jul 29, 2022 07:00AM
May 18, 2022 04:01PM
May 18, 2022 04:01PM
May 9, 2022 04:01PM
Mar 29, 2022 07:00AM
Mar 29, 2022 07:00AM Enanta Pharmaceuticals Receives FDA Fast Track Designation for EDP-235, its Oral 3CL Protease Inhibitor Specifically Designed for the Treatment and Prevention of COVID-19
Feb 17, 2022 07:03AM
Feb 17, 2022 07:00AM
Feb 8, 2022 04:01PM
Jan 6, 2022 07:00AM
Oct 4, 2021 07:06AM
Oct 4, 2021 07:00AM
Jan 8, 2021 07:06AM Enanta Pharma (ENTA) to Provide Updates on its Research and Development Programs and Outlook for 2021 at the 39th Annual J.P. Morgan Healthcare Conference
Jan 8, 2021 07:01AM
Nov 23, 2020 05:23PM
Nov 23, 2020 04:01PM
Sep 14, 2020 07:02AM
Sep 14, 2020 07:00AM
Jul 9, 2020 07:07AM
Jul 9, 2020 07:01AM Enanta Pharmaceuticals Announces Clinical Trial Progress for EDP-514, its Lead Core Inhibitor for Hepatitis B Virus
Mar 26, 2020 04:05PM
Sep 26, 2019 08:00PM
Jul 8, 2019 07:31AM
Jul 8, 2019 07:30AM
Nov 13, 2018 11:40AM
Nov 13, 2018 11:31AM
Nov 13, 2018 11:30AM AbbVie's MAVYRET™ (glecaprevir/pibrentasvir) Shows High Virologic Cure* Rates in Treatment-Naïve Hepatitis C Patients with Compensated Cirrhosis
May 8, 2018 04:00PM
Apr 12, 2018 02:00AM
Mar 28, 2018 07:31AM
Mar 28, 2018 07:30AM
Jan 5, 2018 07:48AM
Jan 5, 2018 07:30AM
Nov 20, 2017 04:01PM Enanta Pharmaceuticals Reports Financial Results for its Fourth Quarter and Year Ended September 30, 2017
Oct 11, 2017 03:03PM

251,774 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All